Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	We kindly request your action: To continue receiving your Amedeo newsletters, please confirm your subscription by October 1, 2023. Please check your weekly Amedeo newsletter.

Tuberculosis

Free Subscription Articles published in Eur Respir J Retrieve available abstracts of 83 articles: HTML format

Single Articles

September 2023
1. RIOU C, du Bruyn E, Kim GHJ, da Costa I, et al
   Derivation of a high-resolution CT-based, semi-automated radiographic score in tuberculosis and its relationship to bacillary load and antitubercular therapy.
   Eur Respir J. 2023 Sep 7:2300600. doi: 10.1183/13993003.00600-2023.
   PubMed    
   
   
   
2. BYRNE A, Allwood B, Schoeman I, Johnston J, et al
   "Post tuberculosis": the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials.
   Eur Respir J. 2023;62:2300950.
   PubMed     Abstract available
   
   
   August 2023
3. STOCKER SL, Alffenaar JC
   Predicting early bactericidal activity using pre-clinical data for tuberculosis drugs: a platform for model-informed drug discovery and development.
   Eur Respir J. 2023;62:2301108.
   PubMed    
   
   
   
4. ERNEST JP, Goh JJN, Strydom N, Wang Q, et al
   Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs.
   Eur Respir J. 2023;62:2300165.
   PubMed     Abstract available
   
   
   June 2023
5. MIGLIORI GB, Dowdy D, Denholm JT, D'Ambrosio L, et al
   The path to tuberculosis elimination: a renewed vision.
   Eur Respir J. 2023;61:2300499.
   PubMed     Abstract available
   
   
   
6. 
   June Podcast: Path to tuberculosis elimination.
   Eur Respir J. 2023;61:23E6106.
   PubMed    
   
   
   May 2023
7. KOSER CU, Maurer FP
   Minimum inhibitory concentrations and sequencing data have to be analysed in more detail to set provisional epidemiological cut-off values for Mycobacterium tuberculosis complex.
   Eur Respir J. 2023;61:2202397.
   PubMed    
   
   
   
8. 
   Reply: Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis.
   Eur Respir J. 2023;61:2300426.
   PubMed     Abstract available
   
   
   
9. KAHLMETER G, Turnidge J
   The determination of epidemiological cut-off values requires a systematic and joint approach based on quality controlled, non-truncated minimum inhibitory concentration series.
   Eur Respir J. 2023;61:2202259.
   PubMed    
   
   
   November 2022
10. OTTO-KNAPP R, Hacker B, Krieger D, Stete K, et al
    Long-term multidrug- and rifampicin-resistant tuberculosis treatment outcome by new WHO definitions in Germany.
    Eur Respir J. 2022;60:2200765.
    PubMed    
    
    
    September 2022
11. KIM C, Ko Y, Moon JW, Park YB, et al
    Incidence, risk factors, and final causes for misdiagnosis of tuberculosis in the Republic of Korea: a population-based longitudinal analysis.
    Eur Respir J. 2022 Sep 14. pii: 13993003.01461-2022.
    PubMed    
    
    
    August 2022
12. SALUZZO F, Denkinger CM, Cirillo DM
    Improving interferon-gamma release assay interpretation: are IP-10 and MIG the solution?
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
13. ROCHE N, Crichton ML, Goeminne PC, Cao B, et al
    Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    July 2022
14. MATTEELLI A, Alffenaar JC
    Diagnosis and treatment of tuberculosis infection: can it contribute to achieving tuberculosis elimination?
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
15. MASINI T, Kanchar A, Mirzayev F, Viney K, et al
    Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally.
    Eur Respir J. 2022 Jul 1. pii: 13993003.01227-2022.
    PubMed    
    
    
    June 2022
16. CHUNG C, Shin JE, Jeon D, Kang H, et al
    Treatment outcomes of multidrug-resistant tuberculosis with chronic kidney/liver disease.
    Eur Respir J. 2022 Jun 16. pii: 13993003.00930-2022.
    PubMed    
    
    
    May 2022
17. MANTEI A, Meyer T, Schurmann M, Bessler C, et al
    Mycobacterium tuberculosis-specific CD4 T-cell scoring discriminates tuberculosis infection from disease.
    Eur Respir J. 2022 May 26. pii: 13993003.01780-2021.
    PubMed     Abstract available
    
    
    
18. AHMED M, Tezera LB, Elkington PT, Leslie AJ, et al
    The paradox of immune checkpoint inhibition reactivating tuberculosis.
    Eur Respir J. 2022 May 20. pii: 13993003.02512-2021.
    PubMed     Abstract available
    
    
    
19. GUGLIELMETTI L, Gunther G, Leu C, Cirillo D, et al
    Rifapentine access in Europe: growing concerns over key tuberculosis treatment component.
    Eur Respir J. 2022;59.
    PubMed    
    
    
    
20. SPRUIJT I, Joren C, Schimmel H, Procee F, et al
    The identification of prevalent tuberculosis disease through infection screening among high-risk migrants in the Netherlands.
    Eur Respir J. 2022;59.
    PubMed    
    
    
    April 2022
21. DAHL V, Migliori GB, Lange C, Wejse C, et al
    War in Ukraine: an immense threat to the fight against tuberculosis.
    Eur Respir J. 2022;59.
    PubMed    
    
    
    
22. 
    Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment.
    Eur Respir J. 2022;59.
    PubMed    
    
    
    March 2022
23. 
    Epidemiological cutoff values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis.
    Eur Respir J. 2022 Mar 17. pii: 13993003.00239-2022.
    PubMed     Abstract available
    
    
    
24. MIGLIORI GB, Falzon D, Marks GB, Goletti D, et al
    Commemorating World Tuberculosis Day 2022: recent ERJ articles of critical relevance to ending TB and saving lives.
    Eur Respir J. 2022;59.
    PubMed    
    
    
    
25. TORNHEIM JA, Udwadia ZF, Arora PR, Gajjar I, et al
    Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis.
    Eur Respir J. 2022;59.
    PubMed    
    
    
    February 2022
26. DINARDO AR, Gandhi T, Heyckendorf J, Grimm SL, et al
    Gene expression signatures identify biologically and clinically distinct tuberculosis endotypes.
    Eur Respir J. 2022 Feb 15. pii: 13993003.02263-2021.
    PubMed     Abstract available
    
    
    January 2022
27. MARGINEANU I, Akkerman O, Cattaneo D, Goletti D, et al
    Practices of therapeutic drug monitoring in tuberculosis - an international survey.
    Eur Respir J. 2022 Jan 27. pii: 13993003.02787-2021.
    PubMed    
    
    
    
28. FALZON D, den Boon S, Kanchar A, Zignol M, et al
    Global reporting on tuberculosis preventive treatment among contacts.
    Eur Respir J. 2022 Jan 27. pii: 13993003.02753-2021.
    PubMed    
    
    
    
29. UZORKA JW, Bakker JA, van Meijgaarden KE, Leyten EMS, et al
    Biomarkers to identify Mycobacterium tuberculosis-infection among borderline QuantiFERON results.
    Eur Respir J. 2022 Jan 20. pii: 13993003.02665-2021.
    PubMed     Abstract available
    
    
    November 2021
30. GHODOUSI A, Rizvi AH, Khanzada FM, Akhtar N, et al
    In vivo Microevolution of Mycobacterium tuberculosis and transient emergence of atpE_Ala63Pro mutation during treatment in a pre-XDR TB patient.
    Eur Respir J. 2021 Nov 18. pii: 13993003.02102-2021.
    PubMed    
    
    
    
31. 
    Tuberculosis and COVID-19 co-infection: description of the global cohort.
    Eur Respir J. 2021 Nov 11. pii: 13993003.02538-2021.
    PubMed     Abstract available
    
    
    
32. XIN H, Cao X, Zhang H, Feng B, et al
    Protective efficacy of 6-week regimen for latent tuberculosis infection treatment in rural China: 5-year follow-up of a randomised controlled trial.
    Eur Respir J. 2021 Nov 11. pii: 13993003.02359-2021.
    PubMed     Abstract available
    
    
    
33. ZHENG X, Davies Forsman L, Bao Z, Xie Y, et al
    Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug resistant tuberculosis: a multi-centre prospective cohort study in China.
    Eur Respir J. 2021 Nov 4. pii: 13993003.01925-2021.
    PubMed     Abstract available
    
    
    October 2021
34. GUPTE AN, Kumar P, Araujo-Pereira M, Kulkarni V, et al
    Baseline IL-6 is a biomarker for unfavorable tuberculosis treatment outcomes: a multi-site discovery and validation study.
    Eur Respir J. 2021 Oct 28. pii: 13993003.00905-2021.
    PubMed     Abstract available
    
    
    
35. SALUZZO F, Mantegani P, Poletti de Chaurand V, Cirillo DM, et al
    QIAreach QuantiFERON(R)-TB for the diagnosis of M. tuberculosis infection.
    Eur Respir J. 2021 Oct 21. pii: 13993003.02563-2021.
    PubMed    
    
    
    September 2021
36. SPRUIJT I, Joren C, van den Hof S, Erkens C, et al
    Tailored approaches facilitate high completion of tuberculosis infection treatment among migrants.
    Eur Respir J. 2021 Sep 24. pii: 13993003.02077-2021.
    PubMed    
    
    
    
37. DECROO T, Jai K, Aung M, Hossain MA, et al
    Bedaquiline can act as core drug in a standardized treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis.
    Eur Respir J. 2021 Sep 24. pii: 13993003.02124-2021.
    PubMed    
    
    
    
38. CHESOV E, Chesov D, Maurer FP, Andres S, et al
    Emergence of bedaquiline-resistance in a high-burden country of tuberculosis.
    Eur Respir J. 2021 Sep 9. pii: 13993003.00621-2021.
    PubMed     Abstract available
    
    
    August 2021
39. MIGLIORI GB, Thong PM, Alffenaar JW, Denholm J, et al
    Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study.
    Eur Respir J. 2021 Aug 26. pii: 13993003.01786-2021.
    PubMed    
    
    
    
40. LINH NN, Viney K, Gegia M, Falzon D, et al
    World Health Organization treatment outcome definitions for tuberculosis: 2021 update.
    Eur Respir J. 2021;58.
    PubMed    
    
    
    July 2021
41. ALAGNA R, Cabibbe AM, Miotto P, Saluzzo F, et al
    Is the new WHO definition of extensively drug-resistant tuberculosis easy to apply in practice?
    Eur Respir J. 2021;58.
    PubMed    
    
    
    
42. TE BRAKE LHM, de Jager V, Narunsky K, Vanker N, et al
    Increased bactericidal activity but dose-limiting intolerability at 50 mg.kg(-1) rifampicin.
    Eur Respir J. 2021;58.
    PubMed     Abstract available
    
    
    June 2021
43. KHAN PY, Franke MF, Hewison C, Seung KJ, et al
    All-oral longer regimens are effective for the management of multidrug resistant tuberculosis in high burden settings.
    Eur Respir J. 2021 Jun 17. pii: 13993003.04345-2020.
    PubMed     Abstract available
    
    
    
44. SAAVEDRA B, Mambuque E, Nguenha D, Gomes N, et al
    Performance of Xpert MTB/RIF Ultra for tuberculosis diagnosis in the context of passive and active case finding.
    Eur Respir J. 2021 Jun 17. pii: 13993003.00257-2021.
    PubMed     Abstract available
    
    
    
45. ORIKIRIZA P, Smith J, Ssekyanzi B, Nyehangane D, et al
    Tuberculosis diagnostic accuracy of stool Xpert MTB/RIF and urine AlereLAM in vulnerable children.
    Eur Respir J. 2021 Jun 17. pii: 13993003.01116-2021.
    PubMed     Abstract available
    
    
    
46. SHIVAKOTI R, Newman JW, Hanna LE, Queiroz ATL, et al
    Host Lipidome and Tuberculosis Treatment Failure.
    Eur Respir J. 2021 Jun 17. pii: 13993003.04532-2020.
    PubMed     Abstract available
    
    
    
47. VILLA S, Tagliani E, Borroni E, Castellotti PF, et al
    Outbreak of pre- and extensively drug-resistant tuberculosis in northern italy: urgency of cross-border, multidimensional, surveillance systems.
    Eur Respir J. 2021 Jun 3. pii: 13993003.00839-2021.
    PubMed    
    
    
    
48. GUGLIELMETTI L, Varaine F
    The coming-of-age of bedaquiline: a tale with an open ending.
    Eur Respir J. 2021;57.
    PubMed    
    
    
    May 2021
49. PENN-NICHOLSON A, Gomathi SN, Ugarte-Gil C, Meaza A, et al
    A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays.
    Eur Respir J. 2021 May 28. pii: 13993003.00526-2021.
    PubMed     Abstract available
    
    
    
50. NOGUERA-JULIAN A, Buonsenso D, Mckenna L, Seddon JA, et al
    Availability of fixed-dose, child-friendly formulations of first-line tuberculosis drugs in Europe.
    Eur Respir J. 2021 May 28. pii: 13993003.01196-2021.
    PubMed    
    
    
    
51. VELEN K, Shingde RV, Ho J, Fox GJ, et al
    The effectiveness of contact investigation among contacts of tuberculosis patients: a systematic review and meta-analysis.
    Eur Respir J. 2021 May 20. pii: 13993003.00266-2021.
    PubMed     Abstract available
    
    
    
52. WEE LE, Goh KCM, Conceicao EP, Tan JBX, et al
    Increased detection of pulmonary tuberculosis amongst hospitalised inpatients during the COVID-19 pandemic.
    Eur Respir J. 2021;57.
    PubMed    
    
    
    
53. GHOSH S, Breitscheidel L, Lazarevic N, Martin A, et al
    Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update.
    Eur Respir J. 2021;57.
    PubMed     Abstract available
    
    
    
54. MAYNARD-SMITH L, Brown CS, Harris RJ, Hodkinson P, et al
    Effectiveness and outcomes of air travel-related TB incident follow-up: a systematic review.
    Eur Respir J. 2021;57.
    PubMed     Abstract available
    
    
    April 2021
55. VEZIRIS N, Bonnet I, Morel F, Guglielmetti L, et al
    Impact of the revised definition of extensively drug resistant tuberculosis.
    Eur Respir J. 2021 Apr 29. pii: 13993003.00641-2021.
    PubMed    
    
    
    
56. MUYOYETA M, Kerkhoff AD, Chilukutu L, Moreau E, et al
    Diagnostic accuracy of a novel point-of-care urine lipoarabinomannan assay for the detection of tuberculosis among adult outpatients in Zambia: a prospective cross-sectional study.
    Eur Respir J. 2021 Apr 29. pii: 13993003.03999-2020.
    PubMed     Abstract available
    
    
    
57. VAN DEUN A, Decroo T, Aung KJM, Hossain MA, et al
    Mycobacterium tuberculosis borderline rpoB mutations: emerging from the unknown.
    Eur Respir J. 2021 Apr 29. pii: 13993003.00783-2021.
    PubMed    
    
    
    
58. HAMADA Y, Cirillo DM, Matteelli A, Penn-Nicholson A, et al
    Tests for tuberculosis infection: landscape analysis.
    Eur Respir J. 2021 Apr 19. pii: 13993003.00167-2021.
    PubMed     Abstract available
    
    
    
59. VINEY K, Linh NN, Gegia M, Zignol M, et al
    New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization.
    Eur Respir J. 2021;57.
    PubMed    
    
    
    
60. SRIVASTAVA S, Gumbo T
    Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis.
    Eur Respir J. 2021;57.
    PubMed    
    
    
    
61. MAITRE T, Guglielmetti L, Veziris N
    Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies.
    Eur Respir J. 2021;57.
    PubMed    
    
    
    
62. NORDHOLM AC, Lillebaek T
    It is time to optimise the management of latent tuberculosis infection in children.
    Eur Respir J. 2021;57.
    PubMed    
    
    
    March 2021
63. BOHLBRO AS, Hvingelby VS, Rudolf F, Wejse C, et al
    Active case-finding of tuberculosis in general populations and at-risk groups: a systematic review and meta-analysis.
    Eur Respir J. 2021 Mar 25. pii: 13993003.00090-2021.
    PubMed     Abstract available
    
    
    
64. GUPTA RK, Lule SA, Krutikov M, Gosce L, et al
    Screening for tuberculosis among high-risk groups attending London Emergency Departments: A prospective observational study.
    Eur Respir J. 2021 Mar 18. pii: 13993003.03831-2020.
    PubMed    
    
    
    
65. DE VRIES G, Gainaru D, Keizer S, Mahler B, et al
    Human reading versus computer automated reading of chest X-rays in a tuberculosis screening programme in Romania.
    Eur Respir J. 2021 Mar 10. pii: 13993003.04628-2020.
    PubMed    
    
    
    
66. JOUET A, Gaudin C, Badalato N, Allix-Beguec C, et al
    Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs.
    Eur Respir J. 2021;57.
    PubMed     Abstract available
    
    
    February 2021
67. HEYCKENDORF J, Marwitz S, Reimann M, Avsar K, et al
    Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model.
    Eur Respir J. 2021 Feb 11. pii: 13993003.03492-2020.
    PubMed     Abstract available
    
    
    
68. ZHANG N, Savic RM, Boeree MJ, Peloquin C, et al
    Optimising pyrazinamide for the treatment of tuberculosis.
    Eur Respir J. 2021 Feb 4. pii: 13993003.02013-2020.
    PubMed     Abstract available
    
    
    
69. KOHLI M, MacLean E, Pai M, Schumacher SG, et al
    Diagnostic accuracy of centralised assays for TB detection and detection of resistance to rifampicin and isoniazid: a systematic review and meta-analysis.
    Eur Respir J. 2021;57.
    PubMed     Abstract available
    
    
    January 2021
70. HAMADA Y, den Boon S, Maria Cirillo D, Penn-Nicholson A, et al
    Framework for the evaluation of new tests for tuberculosis infection.
    Eur Respir J. 2021 Jan 21. pii: 13993003.04078-2020.
    PubMed     Abstract available
    
    
    
71. SOULEYMANE MB, Piubello A, Lawan IM, Hassane-Harouna S, et al
    High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss.
    Eur Respir J. 2021;57.
    PubMed     Abstract available
    
    
    
72. RADTKE KK, Hibma JE, Hesseling AC, Savic RM, et al
    Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children.
    Eur Respir J. 2021;57.
    PubMed    
    
    
    December 2020
73. CHESOV D, Heyckendorf J, Alexandru S, Donica A, et al
    Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country.
    Eur Respir J. 2020 Dec 17. pii: 13993003.02544-2020.
    PubMed     Abstract available
    
    
    November 2020
74. MIRZAYEV F, Viney K, Linh NN, Gonzalez-Angulo L, et al
    World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
    Eur Respir J. 2020 Nov 26. pii: 13993003.03300-2020.
    PubMed     Abstract available
    
    
    
75. NIKOLAYEVSKYY V, Holicka Y, van Soolingen D, van der Werf MJ, et al
    Impact of COVID-19 pandemic on tuberculosis laboratory services in Europe.
    Eur Respir J. 2020 Nov 12. pii: 13993003.03890-2020.
    PubMed    
    
    
    
76. DAVIES FORSMAN L, Niward K, Kuhlin J, Zheng X, et al
    Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.
    Eur Respir J. 2020 Nov 5. pii: 13993003.03463-2020.
    PubMed    
    
    
    
77. GEBRESELASSIE N, Kasaeva T, Zignol M
    A global strategy for tuberculosis research and innovation.
    Eur Respir J. 2020;56.
    PubMed    
    
    
    October 2020
78. MANDALAKAS AM, Hesseling AC, Kay A, Du Preez K, et al
    Tuberculosis prevention in children: A prospective community based study in South Africa.
    Eur Respir J. 2020 Oct 29. pii: 13993003.03028-2020.
    PubMed     Abstract available
    
    
    
79. GUPTA N, Ish P, Gupta A, Malhotra N, et al
    A profile of a retrospective cohort of 22 patients of COVID-19 with active/treated tuberculosis.
    Eur Respir J. 2020 Oct 22. pii: 13993003.03408-2020.
    PubMed    
    
    
    
80. KWON YS, Jeon D, Kang H, Yim JJ, et al
    Concurrent Use of Bedaquiline and Delamanid for the Treatment of Fluoroquinolone-resistant Multidrug-resistant Tuberculosis: A Nationwide Cohort Study in South Korea.
    Eur Respir J. 2020 Oct 22. pii: 13993003.03026-2020.
    PubMed    
    
    
    September 2020
81. CHIANG CY, Islam T, Xu C, Chinnayah T, et al
    The impact of COVID-19 and the restoration of tuberculosis services in the Western Pacific Region (revised).
    Eur Respir J. 2020 Sep 25. pii: 13993003.03054-2020.
    PubMed    
    
    
    May 2020
82. WONG YJ, Lee SWH
    We must screen refugees to ensure no one is left behind: a case study of Malaysia.
    Eur Respir J. 2020;55.
    PubMed    
    
    
    
83. VAN DEN ELSEN SHJ, Akkerman OW, Jongedijk EM, Wessels M, et al
    Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin.
    Eur Respir J. 2020;55.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: